Index -
P/E -
EPS (ttm) -0.93
Insider Own 8.07%
Shs Outstand 44.68M
Perf Week 3.89%
Market Cap 238.59M
Forward P/E -
EPS next Y -1.05
Insider Trans 0.84%
Shs Float 41.07M
Perf Month 193.41%
Income -41.47M
PEG -
EPS next Q -0.25
Inst Own 12.13%
Short Float 6.85%
Perf Quarter 251.32%
Sales 0.49M
P/S 486.92
EPS this Y -4.78%
Inst Trans -10.89%
Short Ratio 1.72
Perf Half Y 233.75%
Book/sh 1.56
P/B 3.42
EPS next Y -8.26%
ROA -41.90%
Short Interest 2.81M
Perf Year 251.32%
Cash/sh 1.67
P/C 3.19
EPS next 5Y -
ROE -47.07%
52W Range 0.94 - 6.42
Perf YTD 260.81%
Dividend Est. -
P/FCF -
EPS past 5Y 35.42%
ROI -58.24%
52W High -16.82%
Beta 1.95
Dividend TTM -
Quick Ratio 7.41
Sales past 5Y 9.26%
Gross Margin 18.44%
52W Low 468.09%
ATR (14) 0.61
Dividend Ex-Date -
Current Ratio 7.41
EPS Y/Y TTM -4.47%
Oper. Margin -9305.74%
RSI (14) 64.23
Volatility 13.76% 19.11%
Employees 32
Debt/Eq 0.03
Sales Y/Y TTM 26.42%
Profit Margin -8496.93%
Recom 1.00
Target Price 10.50
Option/Short Yes / Yes
LT Debt/Eq 0.02
EPS Q/Q -7.34%
Payout -
Rel Volume 0.53
Prev Close 5.75
Sales Surprise 212.00%
EPS Surprise 21.38%
Sales Q/Q 21.87%
Earnings Feb 29 AMC
Avg Volume 1.63M
Price 5.34
SMA20 17.69%
SMA50 90.51%
SMA200 196.21%
Trades
Volume 863,746
Change -7.13%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-05-22 Initiated
William Blair
Outperform
Dec-08-21 Initiated
Robert W. Baird
Outperform
$19
Aug-09-21 Resumed
Maxim Group
Buy
$30 → $20
Oct-22-20 Initiated
H.C. Wainwright
Buy
$27
Oct-08-20 Initiated
Piper Sandler
Overweight
$25
Mar-21-24 07:55AM
Mar-14-24 08:50AM
08:08AM
Mar-06-24 04:05PM
12:00PM
10:12AM
Loading…
Mar-01-24 10:12AM
Feb-29-24 07:40PM
04:07PM
04:06PM
04:05PM
Feb-26-24 08:00AM
Feb-22-24 08:00AM
Jan-17-24 10:30AM
Nov-20-23 04:05PM
Nov-02-23 04:05PM
04:05PM
Loading…
Oct-26-23 04:05PM
Oct-23-23 08:45AM
Oct-11-23 09:35AM
Sep-26-23 04:05PM
Sep-05-23 08:00AM
Aug-09-23 04:05PM
Aug-07-23 04:05PM
Jul-24-23 05:09PM
Jun-20-23 05:22PM
Jun-05-23 08:00AM
May-04-23 04:10PM
Mar-28-23 08:00AM
Mar-06-23 08:15AM
Mar-04-23 07:11AM
Mar-02-23 04:10PM
08:15AM
Loading…
Feb-27-23 08:15AM
Feb-02-23 08:00AM
Jan-10-23 08:00AM
Nov-21-22 10:52AM
Nov-08-22 08:15AM
Nov-03-22 04:10PM
Sep-12-22 04:05PM
Sep-10-22 07:30AM
Sep-08-22 08:15AM
Sep-06-22 08:00AM
Aug-29-22 08:00AM
Aug-04-22 04:10PM
Jul-05-22 08:30AM
Jul-02-22 09:10AM
May-17-22 08:30AM
May-09-22 08:02AM
May-05-22 04:10PM
Apr-12-22 04:00PM
Apr-08-22 01:05PM
01:05PM
Mar-22-22 09:05AM
Mar-17-22 06:32AM
Mar-08-22 04:45PM
Mar-01-22 08:30AM
Feb-24-22 04:10PM
Feb-17-22 03:02PM
Jan-31-22 06:22PM
Jan-20-22 03:44PM
01:46PM
Jan-18-22 05:00PM
Jan-13-22 09:17AM
Jan-11-22 08:00AM
Jan-10-22 08:00AM
Jan-04-22 08:00AM
Dec-28-21 09:38AM
Dec-21-21 09:38AM
Dec-16-21 09:38AM
Dec-10-21 08:30AM
Dec-08-21 09:38AM
Dec-03-21 08:30AM
Nov-18-21 07:00AM
Nov-14-21 07:18AM
Nov-09-21 08:30AM
Nov-04-21 04:15PM
Oct-28-21 03:06PM
Sep-30-21 08:36PM
Sep-15-21 06:37AM
Sep-08-21 04:00PM
Sep-07-21 08:30AM
Aug-25-21 08:15AM
Aug-06-21 04:15AM
(Simply Wall St.) +11.84%
Aug-05-21 04:15PM
Aug-03-21 03:01PM
Jul-12-21 08:00AM
Jul-06-21 08:30AM
Jun-28-21 08:30AM
Jun-10-21 12:30PM
Jun-08-21 08:30AM
May-24-21 08:35AM
02:09AM
May-20-21 08:30AM
May-06-21 04:10PM
Apr-23-21 11:39AM
Apr-12-21 06:00AM
Apr-10-21 08:30AM
08:30AM
Apr-08-21 08:30AM
Mar-25-21 01:41AM
Mar-11-21 08:30AM
Mar-10-21 04:30PM
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. The firm's clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
PACE GARY W Director Dec 19 '23 Buy 1.37 30,000 41,100 697,761 Dec 19 06:39 PM
Index RUT
P/E 37.67
EPS (ttm) 0.78
Insider Own 2.87%
Shs Outstand 46.48M
Perf Week -0.24%
Market Cap 1.36B
Forward P/E 8.21
EPS next Y 3.56
Insider Trans -8.21%
Shs Float 45.16M
Perf Month -2.31%
Income 41.95M
PEG 3.62
EPS next Q 0.65
Inst Own 106.02%
Short Float 9.02%
Perf Quarter -14.84%
Sales 674.98M
P/S 2.01
EPS this Y 0.08%
Inst Trans 2.38%
Short Ratio 8.02
Perf Half Y -5.86%
Book/sh 18.72
P/B 1.56
EPS next Y 26.54%
ROA 2.58%
Short Interest 4.07M
Perf Year -26.79%
Cash/sh 5.99
P/C 4.88
EPS next 5Y 10.40%
ROE 5.10%
52W Range 25.93 - 48.60
Perf YTD -13.40%
Dividend Est. -
P/FCF 9.74
EPS past 5Y -
ROI 2.92%
52W High -39.88%
Beta 0.76
Dividend TTM -
Quick Ratio 4.17
Sales past 5Y 15.46%
Gross Margin 64.15%
52W Low 12.69%
ATR (14) 1.02
Dividend Ex-Date -
Current Ratio 5.24
EPS Y/Y TTM 155.39%
Oper. Margin 12.94%
RSI (14) 46.48
Volatility 3.31% 3.70%
Employees 712
Debt/Eq 0.67
Sales Y/Y TTM 1.22%
Profit Margin 6.22%
Recom 1.20
Target Price 45.30
Option/Short Yes / Yes
LT Debt/Eq 0.65
EPS Q/Q 316.94%
Payout 0.00%
Rel Volume 1.12
Prev Close 29.04
Sales Surprise 0.35%
EPS Surprise 0.76%
Sales Q/Q 5.40%
Earnings Feb 29 BMO
Avg Volume 507.79K
Price 29.22
SMA20 -1.52%
SMA50 -3.46%
SMA200 -10.25%
Trades
Volume 569,631
Change 0.62%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-07-24 Resumed
JP Morgan
Overweight
$80 → $45
Dec-20-23 Initiated
Raymond James
Outperform
$42
Aug-03-23 Upgrade
TD Cowen
Market Perform → Outperform
$50
Jan-31-23 Resumed
Wedbush
Outperform
$88 → $60
Oct-21-22 Resumed
Jefferies
Buy
$66
Jan-03-22 Resumed
JP Morgan
Overweight
$75 → $83
Jul-26-21 Upgrade
JP Morgan
Neutral → Overweight
$75
Apr-21-21 Resumed
JP Morgan
Neutral
$70
Apr-09-21 Initiated
Berenberg
Buy
$93
Apr-07-21 Resumed
RBC Capital Mkts
Outperform
$86
Feb-11-21 Downgrade
Northland Capital
Outperform → Market Perform
$72 → $75
Jan-21-21 Downgrade
SVB Leerink
Outperform → Mkt Perform
$75
Sep-21-20 Upgrade
Northland Capital
Market Perform → Outperform
$58 → $67
Jul-06-20 Reiterated
Needham
Buy
$52 → $64
May-27-20 Initiated
Guggenheim
Neutral
Apr-07-20 Initiated
Northland Capital
Outperform
$50
Mar-20-20 Upgrade
SVB Leerink
Mkt Perform → Outperform
$44
Feb-24-20 Reiterated
H.C. Wainwright
Buy
$60 → $63
Jan-24-20 Initiated
SunTrust
Buy
Jan-23-20 Initiated
SunTrust
Buy
Show Previous Ratings
Mar-14-24 08:23AM
Mar-13-24 07:00AM
Mar-08-24 11:55PM
Mar-06-24 08:00AM
Mar-04-24 08:28PM
08:38AM
Loading…
Mar-01-24 08:38AM
06:05AM
12:28AM
(Thomson Reuters StreetEvents)
Feb-29-24 10:00AM
09:15AM
08:32AM
08:26AM
(Associated Press Finance)
08:00AM
Feb-22-24 08:00AM
Feb-15-24 08:36AM
08:00AM
Loading…
Feb-07-24 08:00AM
Feb-01-24 10:45AM
Jan-05-24 12:21PM
Jan-04-24 05:00PM
Jan-03-24 08:00AM
Dec-21-23 07:30AM
Dec-06-23 11:13AM
Nov-13-23 10:10AM
Nov-10-23 07:30AM
Nov-07-23 08:00AM
Nov-04-23 10:28AM
Nov-02-23 12:34PM
10:00AM
08:23AM
(Associated Press Finance)
08:00AM
08:00AM
Loading…
Oct-26-23 08:00AM
Oct-12-23 08:00AM
Oct-10-23 08:00AM
Oct-02-23 08:00AM
Sep-27-23 12:07PM
11:50AM
Sep-26-23 04:30PM
Sep-06-23 08:00AM
Aug-03-23 10:03AM
Aug-02-23 12:45PM
08:11AM
08:00AM
Jul-28-23 02:56PM
Jul-26-23 08:00AM
Jun-21-23 08:00PM
Jun-02-23 11:31AM
May-31-23 08:00AM
May-09-23 08:00AM
May-03-23 11:42PM
(Thomson Reuters StreetEvents) -7.17%
05:25PM
03:11PM
08:11AM
08:00AM
Apr-26-23 08:00PM
08:00AM
Apr-20-23 09:20AM
08:00AM
Apr-19-23 08:00AM
Apr-12-23 08:00AM
Apr-03-23 08:00AM
Mar-30-23 11:30AM
Mar-29-23 08:00AM
Mar-27-23 08:00AM
Mar-24-23 08:50AM
Mar-22-23 08:00AM
Mar-09-23 09:17AM
Mar-08-23 08:00AM
Feb-28-23 11:39PM
(Thomson Reuters StreetEvents)
08:00AM
Feb-23-23 08:00AM
Feb-21-23 08:00AM
Jan-05-23 04:30PM
Jan-04-23 08:00AM
Dec-20-22 10:06AM
Dec-13-22 08:00AM
Nov-18-22 01:38PM
Nov-17-22 08:05AM
Nov-14-22 08:00AM
Nov-09-22 05:14AM
Nov-08-22 08:00AM
Nov-04-22 10:54AM
Nov-03-22 09:15AM
08:00AM
Nov-01-22 10:01AM
Oct-27-22 10:02AM
Oct-20-22 08:00AM
Oct-15-22 08:34AM
Oct-13-22 08:00AM
Oct-07-22 02:10PM
(Investor's Business Daily)
Sep-27-22 08:00AM
Sep-21-22 06:04PM
10:08AM
08:00AM
Sep-20-22 08:00AM
Sep-13-22 08:00AM
Sep-08-22 10:42AM
Sep-07-22 11:07AM
07:00AM
Sep-02-22 11:31AM
Aug-10-22 08:00AM
Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
PACE GARY W Director Mar 08 '24 Sale 30.60 90,000 2,754,000 22,127 Mar 08 05:33 PM PACE GARY W Director Mar 07 '24 Sale 30.81 28,257 870,598 112,127 Mar 08 05:33 PM PACE GARY W Director Mar 06 '24 Sale 29.67 1,066 31,628 140,384 Mar 08 05:33 PM WINSTON ROY Chief Medical Officer Aug 02 '23 Sale 34.88 509 17,751 52,440 Aug 04 04:47 PM Riker Lauren Bullaro Senior Vice President, Finance Jul 05 '23 Sale 38.91 643 25,019 22,687 Jul 07 08:04 PM Riker Lauren Bullaro Senior Vice President, Finance Jun 14 '23 Sale 38.42 6,366 244,606 22,687 Jun 16 05:39 PM Williams Kristen Marie Chief Administrative Officer Jun 14 '23 Sale 37.03 6,467 239,473 25,375 Jun 16 05:42 PM Kronenfeld Mark A. Director Jun 08 '23 Option Exercise 29.90 15,000 448,500 32,897 Jun 12 04:16 PM Kronenfeld Mark A. Director Jun 08 '23 Sale 37.04 15,000 555,600 17,897 Jun 12 04:16 PM STACK DAVID M CEO and Chairman Jun 07 '23 Sale 37.87 5,326 201,669 153,781 Jun 07 09:33 PM WINSTON ROY Chief Medical Officer Jun 07 '23 Sale 37.87 1,857 70,315 41,356 Jun 07 09:36 PM Reinhart Charles A. III Chief Financial Officer Jun 07 '23 Sale 37.87 1,371 51,913 33,626 Jun 07 09:29 PM Williams Kristen Marie Chief Administrative Officer Jun 07 '23 Sale 37.87 1,357 51,383 20,892 Jun 07 09:34 PM Ellis Ronald J. Jr. Chief Strategy Officer Jun 07 '23 Sale 37.87 1,162 43,999 30,909 Jun 07 09:20 PM REINHARDT MAX President, Rest of World Jun 07 '23 Sale 37.87 1,099 41,614 29,225 Jun 07 09:28 PM McLoughlin Dennis Chief Customer Officer Jun 07 '23 Sale 37.87 1,057 40,023 38,115 Jun 07 09:24 PM GAUGLER DARYL Chief Operating Officer Jun 07 '23 Sale 37.87 1,047 39,645 21,539 Jun 07 09:22 PM Riker Lauren Bullaro Senior Vice President, Finance Jun 07 '23 Sale 37.87 616 23,325 19,053 Jun 07 09:31 PM SLONIN JONATHAN Chief Clinical Officer Jun 07 '23 Sale 37.87 490 18,554 36,323 Jun 07 09:32 PM STACK DAVID M CEO and Chairman Jun 06 '23 Sale 38.99 5,058 197,216 159,107 Jun 07 09:33 PM MOLLOY ANTHONY Chief Lgl & Compliance Officer Jun 06 '23 Sale 38.55 4,521 174,285 12,877 Jun 07 09:26 PM WINSTON ROY Chief Medical Officer Jun 06 '23 Sale 38.99 1,779 69,365 43,213 Jun 07 09:36 PM Williams Kristen Marie Chief Administrative Officer Jun 06 '23 Sale 38.99 1,301 50,727 22,249 Jun 07 09:34 PM Reinhart Charles A. III Chief Financial Officer Jun 06 '23 Sale 38.99 1,236 48,193 34,997 Jun 07 09:29 PM Ellis Ronald J. Jr. Chief Strategy Officer Jun 06 '23 Sale 38.99 1,114 43,436 32,071 Jun 07 09:20 PM REINHARDT MAX President, Rest of World Jun 06 '23 Sale 38.99 1,054 41,097 30,324 Jun 07 09:28 PM McLoughlin Dennis Chief Customer Officer Jun 06 '23 Sale 38.99 1,014 39,537 39,172 Jun 07 09:24 PM GAUGLER DARYL Chief Operating Officer Jun 06 '23 Sale 38.99 1,005 39,186 22,586 Jun 07 09:22 PM Riker Lauren Bullaro Senior Vice President, Finance Jun 06 '23 Sale 38.99 591 23,044 19,669 Jun 07 09:31 PM SLONIN JONATHAN Chief Clinical Officer Jun 06 '23 Sale 38.99 471 18,365 36,813 Jun 07 09:32 PM MOLLOY ANTHONY Chief Lgl & Compliance Officer Jun 05 '23 Sale 38.28 2,267 86,774 17,398 Jun 07 09:26 PM GAUGLER DARYL Chief Operating Officer Jun 05 '23 Sale 38.74 1,000 38,740 23,591 Jun 07 09:22 PM Brege Laura Director Jun 05 '23 Sale 38.74 600 23,244 9,547 Jun 07 09:18 PM HASTINGS PAUL J Director Jun 05 '23 Sale 38.34 580 22,237 6,599 Jun 07 09:23 PM GAUGLER DARYL Chief Operating Officer May 31 '23 Option Exercise 34.00 2,500 85,000 26,894 Jun 02 06:28 PM GAUGLER DARYL Chief Operating Officer May 31 '23 Sale 39.08 2,500 97,700 24,591 Jun 02 06:28 PM HASTINGS PAUL J Director May 15 '23 Option Exercise 29.90 7,000 209,300 14,179 May 17 04:07 PM HASTINGS PAUL J Director May 15 '23 Sale 41.85 7,000 292,950 7,179 May 17 04:07 PM PACE GARY W Director May 11 '23 Option Exercise 29.90 7,000 209,300 144,690 May 15 06:53 PM PACE GARY W Director May 11 '23 Sale 41.78 5,015 209,527 139,675 May 15 06:53 PM Brege Laura Director Apr 03 '23 Option Exercise 29.90 7,000 209,300 17,147 Apr 05 04:34 PM Brege Laura Director Apr 03 '23 Sale 40.72 7,000 285,040 10,147 Apr 05 04:34 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite